Amneal PharmaceuticalsSTU:2DT +0.68%61 EV-to-FCF is 43.45 as of Jul. 08, 2026, which is 101% above its 10-year median of 21.66. GuruFocus rates STU:2DT with a GF Score™ of 61/100 and a GF Value™ of €6.55 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 564 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 69.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Amneal Pharmaceuticals's Enterprise Value is €6,980 Mil.
Amneal Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €161 Mil. Therefore, Amneal Pharmaceuticals's EV-to-FCF for today is 43.45.
The historical rank and industry rank for Amneal Pharmaceuticals's EV-to-FCF or its related term are showing as below:
STU:2DT'
s EV-to-FCF Range Over the Past 10 Years
Min: -581.71 Med: 21.66 Max: 252.73
Current: 42.02
During the past 10 years, the highest EV-to-FCF of Amneal Pharmaceuticals was 252.73. The lowest was -581.71. And the median was 21.66.
STU:2DT's EV-to-FCF is ranked worse than 69.5% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.75
vs STU:2DT: 42.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amneal Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Amneal Pharmaceuticals's share price for today is €14.90.
Amneal Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.328.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's EV-to-FCF falls into.
Amneal Pharmaceuticals's current Enterprise Value is €6,980 Mil.
Amneal Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €161 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (STU:2DT) has a EV-to-FCF of 43.45 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Amneal Pharmaceuticals and its competitors. This is 101% above median its historical median of 21.66. According to the industry distribution chart, Amneal Pharmaceuticals ranks #392 out of 564 companies in the Drug Manufacturers industry, placing it in the top 69.5%.
Is Amneal Pharmaceuticals' EV-to-FCF too high?
Amneal Pharmaceuticals' current EV-to-FCF of 43.45 is 101% above median its 10-year median of 21.66. The Drug Manufacturers industry median EV-to-FCF is 20.75. Amneal Pharmaceuticals' value of 43.45 is 109.4% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #392 out of 564 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amneal Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' EV-to-FCF compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #392 out of 564 companies for EV-to-FCF. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.75. Amneal Pharmaceuticals' value of 43.45 is 109.4% above this benchmark. While the company's 10-year median is 21.66 vs. the industry median of 20.75, Amneal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.75, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current EV-to-FCF of 43.45 is 109.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current EV-to-FCF is 43.45, which is 101% above median its own 10-year median of 21.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (STU:2DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.55, compared to a current price of €14.90 — trading 127.5% above its estimated fair value. The current EV-to-FCF is 43.45, which is 101% above median its 10-year median of 21.66 and 109.4% above the Drug Manufacturers industry median of 20.75. Amneal Pharmaceuticals' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Amneal Pharmaceuticals (STU:2DT), the current EV-to-FCF is 43.45 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (STU:2DT) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of €14.90 is trading 127.5% above its estimated GF Value™ of €6.55.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:2DT:
EV-to-FCF: 43.45 (101% above median its 10-year median of 21.66)
GF Value™: €6.55 vs. price of €14.90 (127.5% above fair value)
Industry Position: 109.4% above the Drug Manufacturers median (#392 of 564)
No single metric tells the full story. See the STU:2DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
61GF Score
Get the complete analysis for STU:2DT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2DT has been successfully added to your 
